Literature DB >> 6759224

Postreceptor defects causing insulin resistance in normoinsulinemic non-insulin-dependent diabetes mellitus.

J Bolinder, J Ostman, P Arner.   

Abstract

The mechanisms of the diminished hypoglycemic response to insulin in non-insulin-dependent diabetes mellitus (NIDDM) with normal levels of circulating plasma insulin were investigated. Specific binding of mono-125I (Tyr A14)-insulin to isolated adipocytes and effects of insulin (5--10,000 microunits/ml) on glucose oxidation and lipolysis were determined simultaneously in subcutaneous adipose tissue of seven healthy subjects of normal weight and seven untreated NIDDM patients with normal plasma insulin levels. The two groups were matched for age, sex, and body weight. Insulin binding, measured in terms of receptor number and affinity, was normal in NIDDM, the total number of receptors averaging 350,000 per cell. Neither sensitivity nor the maximum antilipolytic effect of insulin was altered in NIDDM patients as compared with control subjects; the insulin concentration producing half the maximum effect (ED50) was 10 microunits/ml. As regards the effect of insulin on glucose oxidation, for the control subjects ED50 was 30 microunits/ml, whereas in NIDDM patients, insulin exerted no stimulatory effect. The results obtained suggest that the effect of insulin on glucose utilization in normoinsulinemic NIDDM may be diminished in spite of normal insulin binding to receptors. The resistance may be due solely to postreceptor defects, and does not involve antilipolysis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6759224     DOI: 10.2337/diab.31.10.911

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

1.  Abdominal subcutaneous adipose tissue cellularity in men and women.

Authors:  D P Andersson; E Arner; D E Hogling; M Rydén; P Arner
Journal:  Int J Obes (Lond)       Date:  2017-06-20       Impact factor: 5.095

Review 2.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

Review 3.  Insulin receptor- and nonreceptor-controlled cellular substrate processing. A review of clinical studies in the isolated human adipocyte model.

Authors:  O Pedersen
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

4.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes.

Authors:  J F Caro; M K Sinha; S M Raju; O Ittoop; W J Pories; E G Flickinger; D Meelheim; G L Dohm
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

Review 5.  Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

Authors:  M B Davidson
Journal:  West J Med       Date:  1985-02

6.  Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and Type 2 (non-insulin-dependent) diabetic patients.

Authors:  E Standl; H J Kolb
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

7.  Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.

Authors:  L C Groop; R C Bonadonna; S DelPrato; K Ratheiser; K Zyck; E Ferrannini; R A DeFronzo
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Insulin action in human adipose tissue in acromegaly.

Authors:  J Bolinder; J Ostman; S Werner; P Arner
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Studies of the human liver insulin receptor in noninsulin-dependent diabetes mellitus.

Authors:  P Arner; K Einarsson; S Ewerth; J Livingston
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

10.  Influence of obesity on the antilipolytic effect of insulin in isolated human fat cells obtained before and after glucose ingestion.

Authors:  P Arner; J Bolinder; P Engfeldt; J Hellmér; J Ostman
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.